Urine microRNAs as potential noninvasive biomarkers in urologic cancers

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 41.e1-41.e9

  Mlcochova, Hana ^a,b   Hezova, Renata ^a,b   Stanik, Michal ^b   Slaby, Ondrej ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Biomarker; Bladder cancer; Diagnosis; MicroRNA; Prostate cancer; Renal cell carcinoma; Urologic cancer; Urothelial cancer

Indexed keywords

MICRORNA;

BLADDER CANCER; CANCER DIAGNOSIS; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; REVIEW; RNA STABILITY; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; URINE;

BIOMARKER; BLADDER CANCER; DIAGNOSIS; MICRORNA; PROSTATE CANCER; RENAL CELL CARCINOMA; UROLOGIC CANCER; UROTHELIAL CANCER;

HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; PROGNOSIS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84890793475     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.04.011     Document Type: Review

References (41)

1. Netto G.J. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?. Nat Rev Urol 2012, 9:41-51.
2. Visone R., Croce C.M. MiRNAs and cancer. Am J Pathol 2009, 174:1131-1138.
3. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
4. Slaby O., Jancovicova J., Lakomy R., et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 2010, 29:90.
5. Slaby O., Redova M., Poprach A., et al. Identification of microRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012, 51:707-716.
6. Weber J.A., Baxter D.H., Zhang S., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
7. Redova M., Poprach A., Nekvindova J., et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012, 10:55.
8. Jung M., Schaefer A., Steiner I., et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010, 56:998-1006.
9. Mattie M.D., Benz C.C., Bowers J., et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24.
10. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010, 101:2087-2092.
11. Zhang J., Zhao H., Gao Y., et al. Secretory miRNAs as novel cancer biomarkers. Biochim Biophys Acta 2012, 1826:32-43.
12. Wang K., Zhang S., Weber J., et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010, 38:7248-7259.
13. Chen X, Zhang J, Zen K, et al.: MicroRNAs as blood-based biomarkers of cancer microRNAs in cancer translational research; in Cho WCS (ed), Springer Netherlands, 2011, pp 499-532.
14. Zen K., Zhang C.Y. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012, 32:326-348.
15. Nilsson J., Skog J., Nordstrand A., et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009, 100:1603-1607.
16. Skog J., Wurdinger T., van Rijn S., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
17. Beltrami C., Clayton A., Phillips A.O., et al. Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans 2012, 40:875-879.
18. Yun S.J., Jeong P., Kim W.T., et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012, 41:1871-1878.
19. Hanke M., Hoefig K., Merz H., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010, 28:655-661.
20. Imbeaud S., Graudens E., Boulanger V., et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 2005, 33:e56.
21. Lam BSM, Rghei N, Haj-Ahmad Y. Norgen Biotek Corporation, Application Note 47, RNA Sample Preparation. Revised guidelines for RNA quality assessment for diverse biological sample input, 〈〉; 2012. http://www.norgenbiotek.com/display-resource.php?ID=1728.
22. Wang G., Chan E.S., Kwan B.C., et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 2012, 10:106-113.
23. Shi X.B., Xue L., Yang J., et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007, 104:19983-19988.
24. Cao P., Deng Z., Wan M., et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010, 9:108.
25. Poliseno L., Salmena L., Riccardi L., Fornari A., Song M.S., Hobbs R.M., et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010, 3:ra29.
26. Zaman M.S., Thamminana S., Shahryari V., et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One 2012, 7:e50203.
27. Neal C.S., Michael M.Z., Rawlings L.H., et al. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med 2010, 8:64.
28. Mikhaylova O., Stratton Y., Hall D., et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell 2012, 21:532-546.
29. Liu F., Lou Y.L., Wu J., et al. Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res 2012, 35:182-191.
30. McConkey D.J., Choi W., Marquis L., et al. Role of epithelial-to mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009, 28:335-344.
31. Vinall R.L., Ripoll A.Z., Wang S., et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 2012, 130:2526-2538.
32. Fendler A., Stephan C., Yousef G.M., et al. MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem 2011, 57:954-968.
33. Vrooman O.P., Witjes J.A. Urinary markers in bladder cancer. Eur Urol 2008, 53:909-916.
34. Yamada Y., Enokida H., Kojima S., et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011, 102:522-529.
35. Snowdon J., Boag S., Feilotter H., et al. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J 2012, 1-5.
36. Caplan A., Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 2002, 117(Suppl. 1):S104-108.
37. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
38. Ahumada-Tamayo S., Saavedra-Briones D., Cantellano-Orozco M., et al. MicroRNA determination in urine for prostate cancer detection in Mexican Patients at the Hospital General "Dr. Manuel Gea González". Rev Mex Urol 2011, 71:213-217.
39. Bryant R.J., Pawlowski T., Catto J.W., et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012, 106:768-774.
40. Chow T.F., Youssef Y.M., Lianidou E., et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43:150-158.
41. von Brandenstein M., Pandarakalam J.J., Kroon L., et al. MicroRNA 15a, inversely correlated to PKCα, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 2012, 180:1787-1797.